Skip to main content

Advertisement

Fig. 8 | Journal of Ovarian Research

Fig. 8

From: Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53

Fig. 8

Mitochondrial p53 constructs are tested in combination with paclitaxel in ID8. (A) No drug (transfection only) group was added as the control (no paclitaxel). (b) The respective gene construct was used in combination with 30 nM paclitaxel. (c) 60 nM paclitaxel was used in combination treatment. (d) The apoptotic activities from panel (a) to (c) are compared across different paclitaxel concentrations. The cells were transfected with the respective gene constructs, and the drugs were added 4 h after transfection at 2 different doses (30 nM and 60 nM). 48 h post-transfection, the cells were collected and analyzed using 7-AAD assay (48 h post-transfection). Error bars represent standard deviations from triplicates (n = 3). **p < 0.01, ***p < 0.001

Back to article page